• Healthcare Professionals

    Healthcare Professionals

    Advanced Wound Care

    Diabetic Foot Ulcer

    Debridement

    ChloraSolv

  • Products

    Products

    The Innovation

    ChloraSolv

  • About Us

    About US

    CEO Message

    About us

    Strategy & Values

    Code of Conduct

    Career

  • R&D

    Research & Development

    Introduction

    The Unique Buffered Hypochlorite Technical Platform

    Advanced Wound Care

    Publications & Articles

  • Investors

    Investors

    Introduction

    Strategy

    Management

    Shares

    Calendar

    Investor Relations Contact

  • Financial Information

    Financial Information

    Introduction

    Annual Reports

    Financial Reports

    Regulatory Information

    Invitations

    List of Owners

    Financial Archive

  • Partnership

    Partnership

    Partnership Philosophy

    Our Partners

    Our Distributors

  • Media

    Media

    Introduction

    Press Releases

    News

    Newsletter

    Events

    Images

    Media Contact

  • Rights issue
  • Contact
logo
Regulatory Information
  1. Home
  2. Investor
  3. Regulatory Information

Financial Information

Annual Reports  |  Financial Reports | Regulatory Information | Invitations  |  List of Owners  |  Financial Archive

  • Show all
  • Press Releases SWE
  • Regulatory SWE
  • Regulatory ENG
  • Press Releases ENG

Kallelse till extra bolagsstämma i RLS Global AB (publ)

January 24, 2023

Read More


Press Releases SWE,Regulatory SWE

Lars Johansson nominated as new Chairman of the Board of RLS Global AB

January 24, 2023

Read More


Regulatory ENG,Press Releases ENG

Lars Johansson nominerad till ny styrelseordförande i RLS Global AB

January 24, 2023

Read More


Press Releases SWE,Regulatory SWE

RLS Global: The rights issue is registered and the trading in Paid Subscription Shares ceases

December 9, 2022

Read More


Press Releases ENG

RLS Global: Emissionen registrerad och handeln med BTA upphör

December 9, 2022

Read More


Press Releases SWE

RLS Global AB (publ) delårsrapport juli–september 2022

November 24, 2022

Read More


Press Releases SWE,Regulatory SWE

RLS Global AB (publ) Interim Report, Q3, 2022

November 24, 2022

Read More


Regulatory ENG,Press Releases ENG

RLS Global: Outcome in RLS Global’s rights issue

November 14, 2022

Read More


Regulatory ENG,Press Releases ENG

RLS Global: Utfall i RLS Global företrädesemission

November 14, 2022

Read More


Press Releases SWE,Regulatory SWE

Presentation by Björn Larsson, CEO, RLS Global AB, about the company’s operations and the currently ongoing rights issue

November 10, 2022

Read More


Press Releases ENG

  • 1
  • 2
  • 3
  • …
  • 17

About RLS Global


RLS Global is a Swedish MedTech company based in Gothenburg, founded in 1996. Through our advanced and unique Buffered Hypochlorite based Technology Platform we focus on developing products based on Gentle methods for Minimally Invasive Treatment.

General Privacy Policy

Cookie Policy

Visit us


RLS Global AB
Neongatan 5
SE 431 53 Mölndal
Sweden

Contacts


Customer Services & Orders:
+46 31 780 68 20
customer@rlsglobal.com

Office
+46 31 780 68 20
customer@rlsglobal.com

© 2020 RLS Global. All rights reserved.

Privacy Preference Center

Privacy Preferences

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

  • How does it work?
  • Using ChloraSolv

How does it work?

  • ChloraSolv provides a moist alkaline pH environment that softens and dissolves necrotic tissue and makes it easy to remove by using a blunt instrument.
  • ChloraSolv contains sodium hypochlorite that has the ability to degrade necrotic tissue and facilitate the cleaning.
  • ChloraSolv contains sodium hypochlorite that is a broad-spectrum anti-microbiological agent that reduces the microbiological load as shown in vitro (pH Eur 5.1.11).

Using ChloraSolv
ChloraSolv consists of two solutions provided in a double syringe. The solutions are mixed to form a gel at the time of use. The gel is applied on the wound bed and allowed to act for 2 minutes to soften the devitalized tissue. A blunt instrument is then used to help in the mechanical removal devitalized tissue from the application site. Finish the procedure with a second application of the gel directly onto the wound area to completely clean the wound bed.

ChloraSolv – a valuable addition in the treatment of infected diabetic foot ulcers providing non-surgical debridement

Cookies

We use cookies to help us deliver our services and provide personalised experiences. By using this website, you agree to our use of cookies.

We use cookies to help us deliver our services and provide personalised experiences. By using this website, you agree to our use of cookies.I agreeCookie Policy